z-logo
open-access-imgOpen Access
Drugs potentially affecting the extent of airways reversibility on pulmonary function testing are frequently consumed despite guidelines
Author(s) -
Jones,
Southcott,
Sean Homan
Publication year - 2013
Publication title -
international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s44612
Subject(s) - medicine , affect (linguistics) , pulmonary function testing , pharmacy technician , drug , bronchodilator , pharmacy , intensive care medicine , asthma , emergency medicine , pharmacology , family medicine , philosophy , linguistics
The increase in forced expiratory volume in one second (FEV1) effected by a bronchodilator is routinely assessed when patients undertake pulmonary function testing (PFT). Several drug classes can theoretically affect the magnitude of the increase in FEV1. Withholding periods are advised for many but not all such drugs. Anecdotally, many subjects presenting for PFT are found to have taken drugs that might affect the test. We did an audit of patients presenting for PFT to assess the frequency with which FEV1 reversibility might be affected by drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom